Urinary Symptom Flare in 712 125I Prostate Brachytherapy Patients: Long-Term Follow-Up

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 3, 2009, Pages 649-655

  Keyes, Mira ^a   Miller, Stacy ^a   Moravan, Veronika ^a   Pickles, Tom ^a   Liu, Mitchell ^a   Spadinger, Ingrid ^a   Lapointe, Vincent ^a   Morris, W James ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Predictive factors; Prostate brachytherapy; Prostate cancer; Urinary symptom flare; Urinary toxicity

Indexed keywords

PREDICTIVE FACTORS; PROSTATE BRACHYTHERAPY; PROSTATE CANCER; URINARY SYMPTOM FLARE; URINARY TOXICITY;

DECISION MAKING; MULTIVARIANT ANALYSIS; PATIENT TREATMENT; TUMORS;

TOXICITY;

IODINE 125;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; EDEMA; ERECTILE DYSFUNCTION; FOLLOW UP; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE EDEMA; RADIATION INJURY; RECTUM DISEASE; SCORING SYSTEM; TREATMENT OUTCOME; URINARY TRACT DISEASE; URINARY TRACT OBSTRUCTION; URINARY TRACT STRICTURE; URINE INCONTINENCE;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANDROGEN-BINDING PROTEIN; BRACHYTHERAPY; ERECTILE DYSFUNCTION; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECTUM; URINATION DISORDERS;

EID: 70349559785     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.11.043     Document Type: Article

References (21)

1. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-Year biochemical (prostate-specific antigen) control of prostate cancer with (125) I brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
2. Morris W., Keyes M., Palma D., et al. A population based study of biochemical and survival outcomes following permanent 125 iodine brachytherapy for low- and intermediate-risk prostate cancer. Urology 73 (2009) 860-865
3. Keyes M., Miller S., Moravan V., et al. McKenzie predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: Long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys 73 (2009) 1023-1032
4. Gelblum D.Y., Potters L., Ashley R., et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 45 (1999) 59-67
5. Stone N.N., and Stock R.G. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology 69 (2007) 338-342
6. Keyes M., Schellenberg D., Moravan V., et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve?. Int J Radiat Oncol Biol Phys 64 (2006) 825-834
7. Cesaretti J.A., Stone N.N., and Stock R.G. Late exacerbation of urinary symptoms following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 54 2 Suppl. 1 (2002) 45
8. Morris W.J., Keyes M., Palma D., et al. Evaluation of dosimetric parameters and disease response in 1006 consecutive patients treated with 125-iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 73 (2009) 1432-1438
9. Spadinger I., Hilts M., Keyes M., et al. Prostate brachytherapy post-implant dosimetry: A comparison of suture-embedded and loose seed implants. Brachytherapy 5 (2006) 165-173
10. Blasko J.C., Mate T., Sylvester J.E., et al. Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 12 (2002) 81-94
11. O'Connor R.C., Bales G.T., Avila D., et al. Variability of the International Prostate Symptom Score in men with lower urinary tract symptoms. Scand J Urol Nephrol 37 (2003) 35-37
12. Lawton C.A., Won M., Pilepich M.V., et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 21 (1991) 935-939
13. Macdonald A.G., Keyes M., Kruk A., et al. Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: Is dose to the penile bulb important?. Int J Radiat Oncol Biol Phys 63 (2005) 155-163
14. Lehrer S., Cesaretti J., Stone N.N., et al. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation. BJU Int 98 (2006) 979-981
15. 125iodine prostate brachytherapy. J Urol 179 (2008) 141-146
16. Niehaus A., Merrick G.S., Butler W.M., et al. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 64 (2006) 136-143
17. Rosen R., Altwein J., Boyle P., et al. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol 44 (2003) 637-649
18. Andreassen C.N., Overgaard J., Alsner J., et al. ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after post-mastectomy radiotherapy. Int J Radiat Oncol Biol Phys 64 (2006) 776-783
19. Cesaretti J.A., Stock R.G., Lehrer S., et al. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Int J Radiat Oncol Biol Phys 61 (2005) 196-202
20. Olive P.L., Banath J.P., and Keyes M. Residual gammaH2AX after irradiation of human lymphocytes and monocytes in vitro and its relation to late effects after prostate brachytherapy. Radiother Oncol 86 (2008) 336-346
21. Keyes M., Pugh T., Moore R., et al. Variants in DNA repair genes and their association with late side-effects in prostate brachytherapy patients. Brachytherapy 7 (2008) 122-123